News

How FDA's New Draft Guidance Could Reshape Comp...

FDA's new draft guidance excludes tirzepatide and semaglutide from bulk compounding, potentially ending most compounded GLP-1 access. Here's what

How FDA's New Draft Guidance Could Reshape Comp...

FDA's new draft guidance excludes tirzepatide and semaglutide from bulk compounding, potentially ending most compounded GLP-1 access. Here's what